Vicarious Surgical (NYSE:RBOT) Rating Increased to Hold at Zacks Investment Research

Zacks Investment Research upgraded shares of Vicarious Surgical (NYSE:RBOT) from a sell rating to a hold rating in a report released on Tuesday morning, Zacks.com reports.

According to Zacks, “Vicarious Surgical Inc. is a robotics company developing a disruptive technology. The Company’s novel surgical approach uses a combination of proprietary human-like surgical robots and virtual reality to transport surgeons inside the patient to perform minimally invasive surgery. Vicarious Surgical Inc., formerly known as D8 Holdings Corp., is headquartered in Waltham, Mass. “

A number of other brokerages also recently weighed in on RBOT. BTIG Research assumed coverage on Vicarious Surgical in a report on Monday, October 18th. They issued a buy rating and a $15.00 target price on the stock. Piper Sandler initiated coverage on Vicarious Surgical in a report on Thursday, October 7th. They issued an overweight rating and a $16.00 target price on the stock. Credit Suisse Group initiated coverage on Vicarious Surgical in a report on Friday, January 7th. They issued an outperform rating and a $16.00 price objective on the stock. Cowen initiated coverage on Vicarious Surgical in a report on Tuesday, December 7th. They issued an outperform rating and a $15.00 price objective on the stock. Finally, initiated coverage on Vicarious Surgical in a report on Friday, November 5th. They issued a buy rating and a $15.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of Buy and an average target price of $15.40.

Shares of RBOT opened at $7.10 on Tuesday. Vicarious Surgical has a fifty-two week low of $6.89 and a fifty-two week high of $15.79. The company has a debt-to-equity ratio of 0.09, a quick ratio of 61.49 and a current ratio of 61.49. The firm has a 50-day simple moving average of $11.17.

Vicarious Surgical (NYSE:RBOT) last issued its earnings results on Monday, November 8th. The company reported ($0.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.05). On average, sell-side analysts expect that Vicarious Surgical will post -0.62 EPS for the current fiscal year.

Large investors have recently added to or reduced their stakes in the stock. VK Services LLC bought a new stake in Vicarious Surgical during the third quarter worth approximately $293,386,000. Comprehensive Financial Management LLC bought a new stake in Vicarious Surgical during the third quarter worth approximately $33,472,000. Ghisallo Capital Management LLC bought a new stake in Vicarious Surgical during the third quarter worth approximately $1,496,000. Raymond James & Associates bought a new stake in Vicarious Surgical during the third quarter worth approximately $1,083,000. Finally, Chase Investment Counsel Corp bought a new stake in Vicarious Surgical during the third quarter worth approximately $540,000.

Vicarious Surgical Company Profile

Vicarious Surgical Inc operates as a robotics technology company in the United States. The company focuses on developing and commercializing Vicarious System, a single-incision surgical robot that virtually transports surgeons inside the patient to perform minimally invasive surgery. Vicarious Surgical Inc was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

Read More: What is total return in investing?

Get a free copy of the Zacks research report on Vicarious Surgical (RBOT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Vicarious Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vicarious Surgical and related companies with MarketBeat.com's FREE daily email newsletter.